• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Lower oxygenation does not improve mortality in hypoxemic respiratory failure

byHarsh ShahandDeepti Shroff Karhade
February 9, 2021
in Emergency, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A lower oxygenation target was shown not to decrease the 90-day mortality in patients with acute hypoxemic respiratory failure compared to a high oxygenation target.

2. Additionally, an increase in the median percentage of days alive after hospital discharge was not significantly different in patients between the two oxygenation targets.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with acute hypoxemic respiratory failure receive supplemental oxygen with a high fraction of inspired oxygen (FIO2) within the intensive care unit. A high FIO2 causes a high partial pressure of arterial oxygen (PaO2). Though this therapy is previously associated with increased mortality, no clinical practice guidelines for oxygen targets are present to maximize benefit. As such, this study tested the ability for a five-percentage point reduction in 90-day mortality for a low oxygenation target (PaO2 of 60 mm Hg) compared to a high oxygenation target (PaO2 of 90 mm Hg). The study determined a lower oxygenation target did not reduce the 90-day mortality in patients compared to the higher oxygenation target. The randomized control trial was limited by the trial oxygenation targets may not be the standard of care in some countries. Therefore, the validity of the findings may not be universally applied at institutions with different practices. Nonetheless, this study’s results are significant, and its findings highlight no difference between a lower and higher oxygenation target in lowering the 90-day mortality for acute hypoxemic respiratory failure.

Click to read the study in NEJM

Relevant Reading: Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial

RELATED REPORTS

Oxygen therapy for 15 versus 24 hours per day does not change hypoxemia-related mortality

#VisualAbstract: No Difference in Risk Seen in Long-Term Oxygen Therapy for 24 vs 15 Hours per Day in Severe Hypoxemia

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

In-Depth [randomized controlled trial]: This randomized control trial enrolled 2,928 participants in a multicenter study at 35 sites in seven European countries. Participants included in the study were ≥ 18 years of age, hospitalized with hypoxemic respiratory failure, and received at least 10 liters of oxygen per minute in an open system. Participants unable to undergo randomization within 12 hours of hospitalization were excluded from this study. The participants were randomized in a 1:1 ratio to receive oxygen therapy targeting a PaO2 of 60 mm Hg or 90 mm Hg, respectively. The primary endpoint was death from any cause within 90 days of randomization.

After 90 days from randomization, the mortality was 42.9% (618 of 1441 participants) in the lower oxygenation group compared to 42.4% (613 of 1147 participants) in the higher oxygenation group (risk ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.64). The odds ratio was 1.06 (95% CI, 0.90 to 1.24; P=0.50) after adjustment for stratification and baseline variables. Furthermore, the median percentage of days participants were alive without life support was 87.8 days in the lower oxygenation group compared to 84.4 days in the higher oxygenation group (P=0.10). Additionally, the median percentage of days participants were alive after hospital discharge was 55.6 days in the lower oxygenation group compared to 50.0 days in the higher oxygenation group (P=0.67). Finally, serious adverse events between the lower oxygenation group (36.1%; 525 of 1453 events) and the higher oxygenation group (38.1%; 555 of 1457 events) were not significantly different (P=0.24). Taken together, a lower oxygenation target did not reduce 90-day mortality in acute hypoxemic respiratory failure compared to a higher oxygenation target.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: oxygen therapyrespiratory failure
Previous Post

Low and middle-income countries show greater post-operative mortality following cancer surgery

Next Post

Naltrexone-bupropion treatment provides a higher response for methamphetamine use disorder

RelatedReports

Palliative chemotherapy associated with more ICU treatment at end-of-life
Emergency

Oxygen therapy for 15 versus 24 hours per day does not change hypoxemia-related mortality

October 2, 2024
#VisualAbstract: No Difference in Risk Seen in Long-Term Oxygen Therapy for 24 vs 15 Hours per Day in Severe Hypoxemia
StudyGraphics

#VisualAbstract: No Difference in Risk Seen in Long-Term Oxygen Therapy for 24 vs 15 Hours per Day in Severe Hypoxemia

September 23, 2024
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

July 7, 2022
Large proportion of late preterm infants and older admitted to the NICU
Chronic Disease

Discharge from pediatric intensive care unit after respiratory failure may be associated with long-term impact on neurocognition

March 2, 2022
Next Post
Primary care physicians play substantial role in pediatric mental health

Naltrexone-bupropion treatment provides a higher response for methamphetamine use disorder

#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

#VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Pregnancy outcomes in women with moderate-to-severe psoriasis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]
  • Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
  • An absence of cardiovascular risk factors is linked to over ten additional healthy years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.